Intrahepatic Cholangiocarcinoma Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working, DelveInsight | Incyte Corporation, Roche, Delcath Systems, Basilea Pharmaceutica, Agios Pharmaceuticals, Bayer, Loxo Oncology/Bayer, Qed Therap

Intrahepatic Cholangiocarcinoma emerging therapies such as PEMAZYRE (pemigatinib), ROZLYTREK (entrectinib), TIBSOVO (ivosidenib), CTX-009, Tinengotinib, Silmitasertib (CX-4945), and others are expected to boost the Intrahepatic Cholangiocarcinoma Market in the upcoming years.

DelveInsight has launched a new report on "Intrahepatic Cholangiocarcinoma - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Intrahepatic Cholangiocarcinoma, historical and forecasted epidemiology as well as the Intrahepatic Cholangiocarcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Request for a detailed sample report: https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Recent advancements in the Intrahepatic Cholangiocarcinoma Market:
In March 2024, the European Union approved a Phase III clinical trial for cholangiocarcinoma, and the European Medicines Agency awarded Orphan Drug Designation to Tinengotinib for the treatment of biliary tract cancer.
In April 2024, Compass Therapeutics received FDA Fast Track Designation for its investigation of CTX-009 in combination with paclitaxel to treat patients with metastatic or locally advanced biliary tract tumors that have been previously treated.

Some of the key facts of the Intrahepatic Cholangiocarcinoma Market Report:

Intrahepatic cholangiocarcinoma, also known as intrahepatic bile duct cancer, is a rare cancer that originates in the bile ducts within the liver, accounting for approximately 10% of all cholangiocarcinoma cases. Although uncommon, its incidence is rising at an estimated CAGR of ~2% over the forecast period (2024-2034).
In 2023, the United States represented around 50% of the total intrahepatic cholangiocarcinoma market size within the 7MM. Among these countries, the highest number of cases in 2023 were observed in individuals aged 80 and older.
Regarding mutation-specific cases, TP53 mutations were the most prevalent in intrahepatic cholangiocarcinoma across the 7MM in 2023.
Challenges in recruiting an adequate patient pool and obtaining diagnostic samples for recurrent cases hinder the progress of translational research.
The current treatment landscape for cholangiocarcinoma includes complete surgical resection (considered the gold standard) and first-line chemotherapy, both of which are associated with a high rate of disease recurrence.
In 2023, the United States represented approximately 30% of the total incident cases of cholangiocarcinoma across the 7MM.
According to the analysis, Japan had around 6,400 cases of intrahepatic cholangiocarcinoma in 2023.
Key Intrahepatic Cholangiocarcinoma companies such as Incyte Corporation, Roche, Delcath Systems, Basilea Pharmaceutica, Agios Pharmaceuticals, Bayer, Loxo Oncology/Bayer, Qed Therapeutics, Janssen Pharmaceutical, Taiho Oncology, Redhill Biopharma, Glaxosmithkline, Merck/Glaxosmithkline, Eisai, and others are evaluating new drugs for Intrahepatic Cholangiocarcinoma to improve the treatment landscape.
Promising Intrahepatic Cholangiocarcinoma pipeline therapies in various stages of development include Lorecivivint, EP-104IAR, DFV890, 4P004, GNSC 001, and others.
Key benefits of the Intrahepatic Cholangiocarcinoma market report:
Intrahepatic Cholangiocarcinoma market report covers a descriptive overview and comprehensive insight of the Intrahepatic Cholangiocarcinoma Epidemiology and Intrahepatic Cholangiocarcinoma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Intrahepatic Cholangiocarcinoma market report provides insights on the current and emerging therapies.
Intrahepatic Cholangiocarcinoma market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Intrahepatic Cholangiocarcinoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Intrahepatic Cholangiocarcinoma market.

Got queries? Click here to know more about the Intrahepatic Cholangiocarcinoma Market Landscape https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Intrahepatic Cholangiocarcinoma Overview

Intrahepatic cholangiocarcinoma is a rare and aggressive type of liver cancer that originates in the bile ducts within the liver, accounting for 10-20% of all cholangiocarcinomas, which are cancers arising from the biliary epithelium. It differs from other liver cancers due to its unique cellular origin and growth patterns.

This cancer is often asymptomatic in its early stages, making it difficult to detect until it has advanced significantly. Risk factors include chronic liver conditions like cirrhosis, hepatitis B or C infections, and exposure to certain toxins.

Despite progress in research, intrahepatic cholangiocarcinoma remains difficult to study because of its heterogeneity in both molecular characteristics and clinical presentation. Patients typically experience nonspecific symptoms such as weight loss, abdominal pain, and jaundice, which can delay diagnosis. The cancer's aggressive nature and tendency to be diagnosed at later stages contribute to its poor prognosis.

Gaining a deeper understanding of the biology of intrahepatic cholangiocarcinoma is key to developing more effective treatments. Ongoing research is focused on uncovering the molecular pathways involved in its development and progression, with the aim of identifying new therapeutic targets. However, the rarity of this cancer makes large-scale studies challenging, highlighting the need for greater awareness and early detection to improve patient outcomes.

Intrahepatic Cholangiocarcinoma Treatment Market

Surgical resection is the main curative treatment for intrahepatic cholangiocarcinoma, but only a small proportion of patients are eligible for surgery due to the advanced stage at diagnosis. For those who can undergo resection, the five-year survival rate is notably improved, although recurrence is common. Liver transplantation is an option for certain patients with early-stage intrahepatic cholangiocarcinoma who meet strict criteria, such as tumor size and no metastasis. While this could provide a potential cure, the limited availability of donor organs restricts its use. For patients with inoperable or advanced intrahepatic cholangiocarcinoma, systemic chemotherapy remains the primary treatment. Standard regimens often involve a combination of gemcitabine and cisplatin, which have shown modest effects in extending survival, but response rates are generally low, underscoring the need for more effective treatments. Emerging targeted therapies offer promising alternatives. Drugs targeting genetic mutations like FGFR2 or IDH1/2 have shown clinical benefits for patients with these specific alterations, representing a shift toward personalized medicine and offering hope for better outcomes.

Explore how the intrahepatic cholangiocarcinoma treatment market is growing in the upcoming years @ https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Intrahepatic Cholangiocarcinoma Market Outlook

The intrahepatic cholangiocarcinoma market is progressing with promising developments in targeted and personalized treatments. Despite challenges posed by late diagnosis and the cancer's rarity, the emergence of drugs targeting FGFR2 and IDH-1 mutations provides new hope. The growth of the market is being driven by increased research, advancements in molecular diagnostics, and the rise of precision medicine. However, high treatment costs and difficulties in recruiting participants for clinical trials remain ongoing obstacles. The future outlook is optimistic, with expectations for more treatment options and improved patient outcomes as new therapies are approved and made available.

Intrahepatic Cholangiocarcinoma Marketed Drugs
PEMAZYRE (pemigatinib): Incyte Corporation
ROZLYTREK (entrectinib): Roche
TIBSOVO (ivosidenib): Servier/Agios Pharmaceuticals

Intrahepatic Cholangiocarcinoma Emerging Drugs
CTX-009: Compass Therapeutics
Tinengotinib: TransThera Sciences
Silmitasertib (CX-4945): Senhwa Biosciences

Intrahepatic Cholangiocarcinoma Therapies and Key Companies
TransCon hGH: Ascendis Pharma
HyTropin (GX-H9): Genexine
Somatrogon: OPKO Health

Download our report @ https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Scope of the Intrahepatic Cholangiocarcinoma Market Report

Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Intrahepatic Cholangiocarcinoma Companies: Incyte Corporation, Roche, Delcath Systems, Basilea Pharmaceutica, Agios Pharmaceuticals, Bayer, Loxo Oncology/Bayer, Qed Therapeutics, Janssen Pharmaceutical, Taiho Oncology, Redhill Biopharma, Glaxosmithkline, Merck/Glaxosmithkline, Eisai, and others
Key Intrahepatic Cholangiocarcinoma Therapies: Idebenone, zagociguat, KH176, OMT-28, Sonlicromanol, KL1333, and others
Intrahepatic Cholangiocarcinoma Therapeutic Assessment: Intrahepatic Cholangiocarcinoma current marketed and Intrahepatic Cholangiocarcinoma emerging therapies
Intrahepatic Cholangiocarcinoma Market Dynamics: Intrahepatic Cholangiocarcinoma market drivers and Intrahepatic Cholangiocarcinoma market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Intrahepatic Cholangiocarcinoma Unmet Needs, KOL's views, Analyst's views, Intrahepatic Cholangiocarcinoma Market Access and Reimbursement

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Intrahepatic Cholangiocarcinoma Patient Share (%) Overview at a Glance
5. Intrahepatic Cholangiocarcinoma Market Overview at a Glance
6. Intrahepatic Cholangiocarcinoma Disease Background and Overview
7. Intrahepatic Cholangiocarcinoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Intrahepatic Cholangiocarcinoma
9. Intrahepatic Cholangiocarcinoma Current Treatment and Medical Practices
10. Unmet Needs
11. Intrahepatic Cholangiocarcinoma Emerging Therapies
12. Intrahepatic Cholangiocarcinoma Market Outlook
13. Country-Wise Intrahepatic Cholangiocarcinoma Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Intrahepatic Cholangiocarcinoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Intrahepatic Cholangiocarcinoma Market Outlook 2034 https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Related Reports:

Intrahepatic Cholangiocarcinoma Pipeline Insights, DelveInsight

"Intrahepatic Cholangiocarcinoma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Intrahepatic Cholangiocarcinoma market. A detailed picture of the Intrahepatic Cholangiocarcinoma pipeline landscape is provided, which includes the disease overview and Intrahepatic Cholangiocarcinoma treatment guidelines.

Contact Info:

Kritika Rehani, Team Leader Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.